| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Citalopram Hydrobromide (Lu-10-171) is a potent and FDA approved antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. In control rats, the mono- and polysynaptic reflex amplitudes were reduced to approximately 40–50% of the preadministration value 15 minutes after cyclobenzaprine was administered. It is prescribed off-label for various conditions and has been used to treat major depression. Citalopram hydrobromide acts as a selective inhibitor of serotonin reuptake, meaning that it increases serotonergic activity in the central nervous system by selectively inhibiting the reuptake of serotonin by CNS neurons.
| Targets |
serotonin reuptake ( IC50 = 1.8 nM )
|
|---|---|
| ln Vitro |
Citalopram (Lu 10-171), an exceptionally strong inhibitor of neuronal serotonin (5-HT) uptake, a novel bicyclic phthalane derivative exhibits no antagonistic activity toward 5-HT, histamine, gamma aminobutyric acid (GABA), acetylcholine, and morphine receptors, and has no effect on the uptake of noradrenaline (NA) or dopamine (DA). It is a very strong and selective inhibitor of the uptake of 5-HT by neurons. The medication has no effect on the uptake mechanisms for other transmitter amines[1]. The effects of the SSRI citalopram are more pronounced on proliferation and less pronounced on apoptotic activity. By enhancing proliferative potential and lowering apoptotic activity in a site-specific manner that may be suggestive of hyperplasia, it influences the regulation of the cell cycle. In osteoblast cell culture, citalopram modifies the expression of FGF, MSX, and TGFB[3].
|
| ln Vivo |
Citalopram even when administered in quantities well above the therapeutic range, has no cardiotoxic effects on the animals. Citabram is metabolized in humans to produce substances that are less abundant than citalopram itself but are nevertheless strong 5-HT-uptake inhibitors without affecting noradrenaline (NA) uptake. Citalopram (1–16 mg/kg) causes the spinal rat's hindlimb flexor reflex to fire. Citalopram may increase the amount of 5-HT transmitted by causing marked uptake inhibition without also inhibiting the post-synaptic 5-HT receptors1.
|
| Cell Assay |
Eagles medium (alpha minimum) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and amphotericin B is used to cultivate the cells. The standard alpha proliferation media is used to culture the cells for a duration of 3 or 7 days, providing control data. A dose response curve is obtained for SSRI treatments by supplementing media with citalopram eluted to serially diluted doses between 10−4 mol and 10−10 mol.
|
| Animal Protocol |
Spontaneously Hypertensive rats (SHRs), Lewis (LEW) rats, and Wistar-Kyoto (WKY) rats
1-10 mg/kg i.p. |
| References |
| Molecular Formula |
C20H22BRFN2O
|
|---|---|
| Molecular Weight |
405.3039
|
| Exact Mass |
404.09
|
| Elemental Analysis |
C, 59.27; H, 5.47; Br, 19.71; F, 4.69; N, 6.91; O, 3.95
|
| CAS # |
59729-32-7
|
| Related CAS # |
Citalopram; 59729-33-8; 207559-01-1 (oxalate); 59729-32-7 (HBr)
|
| Appearance |
White to off-white solid powder
|
| SMILES |
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br
|
| InChi Key |
WIHMBLDNRMIGDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H
|
| Chemical Name |
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;hydrobromide
|
| Synonyms |
Lu10-171-BLu-10-171-BCelexa Cipramil Citalopram HBr HSDB 7042 EINECS 261-890-6 Lu 10-171-B CPD000326936
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~81 mg/mL (~199.9 mM)
Water: ~81 mg/mL Ethanol: ~81 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 110 mg/mL (271.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4673 mL | 12.3365 mL | 24.6731 mL | |
| 5 mM | 0.4935 mL | 2.4673 mL | 4.9346 mL | |
| 10 mM | 0.2467 mL | 1.2337 mL | 2.4673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04497168 | Active Recruiting |
Drug: Citalopram 20mg Drug: Placebo |
Parkinson Disease | University of Michigan | April 1, 2021 | Phase 2 |
| NCT04846829 | Active Recruiting |
Drug: Placebo Device: intermittent theta burst stimulation |
Major Depressive Disorder | University of California, Los Angeles |
April 24, 2017 | Early Phase 1 |
| NCT02553161 | Active Recruiting |
Drug: Escitalopram Behavioral: Cognitive behavioral Psychotherapy |
Depression Anxiety Bipolar Disorder |
University of Cincinnati | December 2015 | Not Applicable |
| NCT00667121 | Active Recruiting |
Drug: citalopram hydrobromide Drug: escitalopram oxalate Drug: gabapentin Drug: venlafaxine |
Breast Cancer Depression Hot Flashes |
Mayo Clinic | March 16, 2011 | N/A |
| NCT04623099 | Recruiting | Drug: Escitalopram | Anxiety | University of Cincinnati | March 8, 2021 | Phase 4 |
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
